Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

AI in multiple myeloma: Recent findings and opportunities

Prof Anant Madabhushi - Emory University, Atlanta, USA

AI in multiple myeloma: Recent findings and opportunities ( Prof Anant Madabhushi - Emory University, Atlanta, USA )

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Optimising immunoglobulin dosing can enhance patient outcomes in multiple...

Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma ( Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA )

Oncologists' perspectives and practices on minimal residual disease testing in...

Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA

Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma ( Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA )

The need for improved healthcare infrastructure for extranodal NK/T-cell...

Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America ( Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala )

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

High-fibre dietary intervention in precursor plasma cell disorders improves...

Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma ( Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA )

Lack of benefit of auto-HCT in MCL patients in first complete remission with...

Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD ( Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA )

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r...

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

More from ecancer